Corvus Pharmaceuticals, Inc. Increase (Decrease) in Other Noncurrent Liabilities
Corvus Pharmaceuticals, Inc. (CRVS) reported Increase (Decrease) in Other Noncurrent Liabilities of $12.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2020-03-09
- Corvus Pharmaceuticals, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2018-12-31 was $243.00K.
- Corvus Pharmaceuticals, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2018-09-30 was -$116.00K.
- Corvus Pharmaceuticals, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2018-06-30 was -$114.00K.
- Corvus Pharmaceuticals, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2018-03-31 was -$115.00K.
- Corvus Pharmaceuticals, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2019 was $12.00K.
- Corvus Pharmaceuticals, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2018 was -$102.00K.
- Corvus Pharmaceuticals, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2017 was -$434.00K, a 162.45% decline from fiscal 2016.
- Corvus Pharmaceuticals, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2016 was $695.00K, a 8.76% increase from fiscal 2015.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month | Increase (Decrease) in Other Noncurrent Liabilities 11 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month |
|---|---|---|---|---|---|
| 2019-12-31 | $12.00K 10-K · filed 2020-03-09 | ||||
| 2018-12-31 | $243.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $127.00K derived: sum of 2 quarters · filed 2020-03-09 | $13.00K derived: sum of 3 quarters · filed 2020-03-09 | -$102.00K 10-K · filed 2020-03-09 | |
| 2018-09-30 | -$116.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$230.00K derived: sum of 2 quarters · filed 2018-11-01 | -$345.00K 10-Q · filed 2018-11-01 | -$451.00K derived: sum of 4 quarters · filed 2020-03-09 | |
| 2018-06-30 | -$114.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$229.00K 10-Q · filed 2018-08-02 | -$335.00K derived: sum of 3 quarters · filed 2020-03-09 | -$445.00K derived: sum of 4 quarters · filed 2020-03-09 | |
| 2018-03-31 | -$115.00K 10-Q · filed 2018-05-03 | -$221.00K derived: sum of 2 quarters · filed 2020-03-09 | -$331.00K derived: sum of 3 quarters · filed 2020-03-09 | -$441.00K derived: sum of 4 quarters · filed 2020-03-09 | |
| 2017-12-31 | -$106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | -$216.00K derived: sum of 2 quarters · filed 2020-03-09 | -$326.00K derived: sum of 3 quarters · filed 2020-03-09 | -$434.00K 10-K · filed 2020-03-09 | |
| 2017-09-30 | -$110.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$220.00K derived: sum of 2 quarters · filed 2018-11-01 | -$328.00K 10-Q · filed 2018-11-01 | -$180.00K derived: sum of 4 quarters · filed 2019-03-07 | |
| 2017-06-30 | -$110.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$218.00K 10-Q · filed 2018-08-02 | -$70.00K derived: sum of 3 quarters · filed 2019-03-07 | -$159.00K derived: sum of 4 quarters · filed 2019-03-07 | |
| 2017-03-31 | -$108.00K 10-Q · filed 2018-05-03 | $40.00K derived: sum of 2 quarters · filed 2019-03-07 | -$49.00K derived: sum of 3 quarters · filed 2019-03-07 | $6.00K derived: sum of 4 quarters · filed 2019-03-07 | |
| 2016-12-31 | $148.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $59.00K derived: sum of 2 quarters · filed 2019-03-07 | $114.00K derived: sum of 3 quarters · filed 2019-03-07 | $695.00K 10-K · filed 2019-03-07 | |
| 2016-09-30 | -$89.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | -$34.00K derived: sum of 2 quarters · filed 2017-11-02 | $547.00K 10-Q · filed 2017-11-02 | ||
| 2016-06-30 | $55.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $636.00K 10-Q · filed 2017-08-03 | |||
| 2016-03-31 | $581.00K 10-Q · filed 2017-05-04 | ||||
| 2015-12-31 | $639.00K 10-K · filed 2018-03-01 | ||||
| 2015-06-30 | $13.00K 10-Q · filed 2016-08-04 | ||||
| 2014-12-31 | $3.00K 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |